Immunomedics (IMMU) Presented Results from Clivatuzumab Blood Test in Patients with Early-Stage Pancreatic Cancer
Tweet Send to a Friend
Immunomedics, Inc. (NASDAQ: IMMU) today reported that initial studies indicate that a new blood test using the Company's proprietary antibody ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
